The Phase 3 success removes clinical risk for LUMRYZ in IH, but the 2028 marketing restriction caps near-term revenue upside. Watch for sNDA filing progress and FDA acceptance in H2 2026; any update on the settlement agreement timeline could be a catalyst. The stock may gap up on the clinical data but the delayed commercial launch limits the magnitude.
ALKS drugs
ALKS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $38.26entry
- T+1 · 6mo ago +1.31%α +0.73% · $38.76
- T+5 · 6mo ago −2.79%α −2.87% · $37.19
- T+20 · 5mo ago +14.59%α +16.32% · $43.84
- T+60 · 3mo ago +25.88%α +21.76% · $48.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alkermes announced positive topline results from the REVITALYZ Phase 3 study of LUMRYZ in idiopathic hypersomnia (IH), meeting all primary and key secondary endpoints with high statistical significance (p<0.0001). The company plans to file an sNDA with the FDA by end of 2026, but a prior settlement agreement bars marketing LUMRYZ for IH before March 1, 2028, even if approved. This is a clear clinical win that expands LUMRYZ's addressable market into a rare disease affecting ~40,000 U.S. patients, though commercial upside is delayed by the marketing restriction.
Key Facts
- LUMRYZ met the primary endpoint (ESS, p<0.0001) and all key secondary endpoints (PGI-C, IHSS, both p<0.0001) in the REVITALYZ Phase 3 study for idiopathic hypersomnia.
- Safety profile consistent with known LUMRYZ data; no new safety signals observed.
- Alkermes plans to file a supplemental New Drug Application (sNDA) with the FDA by the end of 2026.
- A prior settlement and license agreement prohibits marketing LUMRYZ for IH before March 1, 2028, even if FDA approval is granted earlier.
- Idiopathic hypersomnia affects an estimated 40,000 people in the U.S., representing a new, addressable rare disease market for LUMRYZ.
Financial Impact
No financial figures provided in the filing. LUMRYZ is already approved for narcolepsy; IH label expansion opens a new market of ~40,000 U.S. patients, but commercialization is barred until March 1, 2028.
Risk Factors
- Marketing restriction until March 1, 2028 limits near-term revenue from IH even if FDA approves.
- FDA may not accept or approve the sNDA; regulatory risk remains.
- Competition from other IH treatments could emerge before 2028.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218150 |
| Document: alks-20260512.htm | 0001193125-26-218150 |
| Document: 0001193125-26-218150-index-headers.html | 0001193125-26-218150 |
| Document: 0001193125-26-218150-index.html | 0001193125-26-218150 |
| Document: 0001193125-26-218150.txt | 0001193125-26-218150 |
Track record
23 reports on ALKS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $46.98 Now $46.53 −0.96% settles Feb 10
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
- Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
- Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
- Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers